Long-Term Survival After Pneumonectomy for Major Hemoptysis in Advanced Non-Small Cell Lung Cancer.

A 65-year-old man was admitted for a tissue biopsy of suspected right middle and lower lobe lung cancer with multiple bone metastases. During hospitalization, he started to cough up blood, which recurred after intubation. The patient experienced asphyxia, which led to cardiopulmonary arrest, but was successfully resuscitated.

Surgical indications for pleurectomy/decortication in pleural mesothelioma based on the newly revised 9th edition of the tumour-node-metastasis classification.

Objectives: The MARS2 trial questioned the efficacy of curative intent surgery for pleural mesothelioma (PM), while real-world clinical data from Japan suggest a favourable prognosis in surgical cases, indicating survival benefits in selected patients. The newly revised 9th edition of the tumour-node-metastasis (TNM) classification introduces a novel indicator based on pleural thickness.

Methods: We conducted a retrospective evaluation of patients with PM who underwent pleurectomy/decortication between 2012 and 2022.

A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement.

Background: Durvalumab after chemoradiation (PACIFIC regimen) provides favorable treatment outcomes for unresectable stage III non-small cell lung cancer (NSCLC). The feasibility of salvage surgery after the PACIFIC regimen has been reported in some studies; however, its efficacy remains unclear. We herein present the first case of salvage surgery after the PACIFIC regimen for a superior sulcus tumor with N3 involvement, in which a pathological complete response was achieved.

Enhanced capture system for mesenchymal‑type circulating tumor cells using a polymeric microfluidic device 'CTC‑Chip' incorporating cell‑surface vimentin.

CellSearch, the only approved epithelial cell adhesion molecule (EpCAM)‑dependent capture system approved for clinical use, overlooks circulating tumor cells (CTCs) undergoing epithelial‑mesenchymal transition (EMT‑CTCs), which is considered a crucial subtype responsible for metastasis. To address this limitation, a novel polymeric microfluidic device 'CTC‑chip' designed for the easy introduction of any antibody was developed, enabling EpCAM‑independent capture. In this study, antibodies against EpCAM and cell surface vimentin (CSV), identified as cancer‑specific EMT markers, were conjugated onto the chip (EpCAM‑chip and CSV‑chip, respectively), and the capture efficiency was examined using lung cancer (PC9, H441 and A549) and colon cancer (DLD1) cell lines, classified into three types based on EMT markers: Epithelial (PC9), intermediate (H441 and DLD1) and mesenchymal (A549).